Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry

DOP43 Long-term efficacy of tofacitinib in patients who received extended induction therapy: results of the OCTAVE open study for tofacitinib delayed responders

(2019) D T Rubin et al.   Journal of Crohns & Colitis

Real-World Experience with Tofacitinib in IBD at a Tertiary Center

(2019) Roni Weisshof et al.   DIGESTIVE DISEASES AND SCIENCES

Eficacia de tofacitinib en el tratamiento de la colitis ulcerosa

(2019) Julián Panés et al.   Gastroenterologia y Hepatologia

Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme

(2019) William J. Sandborn et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open

(2019) Bruce E. Sands et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis

(2019) Loriane Lair-Mehiri et al.   DIGESTIVE AND LIVER DISEASE

Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice

(2019) Javier P Gisbert et al.   Journal of Crohns & Colitis

Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data

(2019) Fumi Varyani et al.   Drug Design Development and Therapy

Acute severe ulcerative colitis: State of the art treatment

(2018) Javier P. Gisbert et al.   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis

(2018) Stephen Hanauer et al.   Clinical Gastroenterology and Hepatology

Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry

(2018) María Chaparro et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials

(2018) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

(2017) Marcus Harbord et al.   Journal of Crohns & Colitis

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

(2017)   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

(2017) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation

(2016) Carlos Taxonera et al.   DIGESTIVE DISEASES AND SCIENCES

Maintenance therapy options for ulcerative colitis

(2016) María Chaparro et al.   EXPERT OPINION ON PHARMACOTHERAPY

Doubling the infliximab dose versus halving the infusion intervals in Crohnʼs disease patients with loss of response

(2012) Lior Katz et al.   INFLAMMATORY BOWEL DISEASES

Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term durability of response to adalimumab in Crohnʼs disease

(2011) M. Chaparro et al.   INFLAMMATORY BOWEL DISEASES

Long-term Durability of Infliximab Treatment in Crohnʼs Disease and Efficacy of Dose “Escalation” in Patients Losing Response

(2011) María Chaparro et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis

(2008) James D. Lewis et al.   INFLAMMATORY BOWEL DISEASES